Summary of PB cellular kinetic parameters for CTL019 transgene by day 28 response and use of tocilizumab
| Parameter . | Received tocilizumab . | No tocilizumab . | ||
|---|---|---|---|---|
| CR/CRi (n = 15) . | NR (n = 0) . | CR/CRi (n = 37) . | NR (n = 3) . | |
| AUC0-28d, copies/µg × d | ||||
| Geometric mean (CV%), n | 893 000 (76.3), 15 | — | 232 000 (137.8), 37 | 105 000 (1170), 3 |
| Cmax, copies/µg | ||||
| Geometric mean (CV%), n | 92 300 (58.8), 15 | — | 36 300 (138), 35 | 17 200 (779.4), 3 |
| Tmax, d | ||||
| Median (range), n | 11 (7-18), 15 | — | 10 (2-31), 35 | 13 (8-16), 3 |
| Parameter . | Received tocilizumab . | No tocilizumab . | ||
|---|---|---|---|---|
| CR/CRi (n = 15) . | NR (n = 0) . | CR/CRi (n = 37) . | NR (n = 3) . | |
| AUC0-28d, copies/µg × d | ||||
| Geometric mean (CV%), n | 893 000 (76.3), 15 | — | 232 000 (137.8), 37 | 105 000 (1170), 3 |
| Cmax, copies/µg | ||||
| Geometric mean (CV%), n | 92 300 (58.8), 15 | — | 36 300 (138), 35 | 17 200 (779.4), 3 |
| Tmax, d | ||||
| Median (range), n | 11 (7-18), 15 | — | 10 (2-31), 35 | 13 (8-16), 3 |